Meredith Mistark

Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study.

S. Sarosiek, V. Sanchorawala, J. Sloan, 2020, Blood.

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

S. Sarosiek, V. Sanchorawala, J. Sloan, 2017 .

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

S. Sarosiek, V. Sanchorawala, J. Sloan, 2018, Blood.